Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?

Source Motley_fool

Key Points

  • Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative.

  • Novo’s steady insulin cash flows and new MASH bet could expand growth beyond its core diabetes focus.

  • 10 stocks we like better than Novo Nordisk ›

Discover how Novo Nordisk (NYSE: NVO) stacks up against Eli Lilly (NYSE: LLY) in the obesity and metabolic race, from GLP‑1 leadership to NASH/MASH optionality and dividend appeal. Watch the video below to see which profile fits your portfolio.

*This video was published on Jun. 26, 2026.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »

Should you buy stock in Novo Nordisk right now?

Before you buy stock in Novo Nordisk, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $382,359!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,201,390!*

Now, it’s worth noting Stock Advisor’s total average return is 883% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of June 26, 2026.

Alicia Alfiere, MBA has no position in any of the stocks mentioned. Danny Vena, CPA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin bears target a $52,000 price level as traders position for a 2026 declineBitcoin crashed to $58,700 on Thursday and now options traders are convinced it will crash as far as $52,000 before the year is over, which would be its lowest level since August 2024. That decline saw Bitcoin fall by almost 52% from its all-time high and left the OG crypto below the $60,000 level, which...
Author  Cryptopolitan
19 hours ago
Bitcoin crashed to $58,700 on Thursday and now options traders are convinced it will crash as far as $52,000 before the year is over, which would be its lowest level since August 2024. That decline saw Bitcoin fall by almost 52% from its all-time high and left the OG crypto below the $60,000 level, which...
placeholder
Iran wants ships to pay for services when crossing the Strait of HormuzIran is trying to turn the Strait of Hormuz into a paid transit system after the ceasefire tied to Trump reopened the waterway. Tehran wants ships to pay for security, safety, and environmental services while crossing the oil route, with officials putting the possible yearly income at about $40 billion for the countries involved, according...
Author  Cryptopolitan
19 hours ago
Iran is trying to turn the Strait of Hormuz into a paid transit system after the ceasefire tied to Trump reopened the waterway. Tehran wants ships to pay for security, safety, and environmental services while crossing the oil route, with officials putting the possible yearly income at about $40 billion for the countries involved, according...
placeholder
OpenAI tilts toward 2027 IPO as Anthropic prepares to list firstOpenAI is leaning toward postponing its initial public offering until 2027, per a New York Times report on June 25 citing people involved in the company’s internal deliberations. The shift represents a reversal from the late-2026 timeline OpenAI has signaled since January, with CEO Sam Altman rejecting any valuation below $1 trillion and CFO Sarah...
Author  Cryptopolitan
20 hours ago
OpenAI is leaning toward postponing its initial public offering until 2027, per a New York Times report on June 25 citing people involved in the company’s internal deliberations. The shift represents a reversal from the late-2026 timeline OpenAI has signaled since January, with CEO Sam Altman rejecting any valuation below $1 trillion and CFO Sarah...
placeholder
SOL Price is Down 20% But Solana Network Activity is Climbing on Meme CoinsSolana (SOL) is down about 20% in a month, and long-term holders keep moving coins onto exchanges to sell, yet on-chain volume, aka Solana network activity, has jumped about 39%.Much of that surge com
Author  Beincrypto
20 hours ago
Solana (SOL) is down about 20% in a month, and long-term holders keep moving coins onto exchanges to sell, yet on-chain volume, aka Solana network activity, has jumped about 39%.Much of that surge com
placeholder
OpenAI Could Reportedly Delay IPO After SpaceX ScareOpenAI executives are reportedly urging caution on its IPO timeline after SpaceX’s turbulent public debut, highlighting risks in mega-AI listings.The development comes as Polymarket traders price roug
Author  Beincrypto
20 hours ago
OpenAI executives are reportedly urging caution on its IPO timeline after SpaceX’s turbulent public debut, highlighting risks in mega-AI listings.The development comes as Polymarket traders price roug
goTop
quote